Polarean Imaging

Pharma Trials And Pediatric FDA Approval Will Open Global Markets

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

11 May 25

Updated

26 Sep 25

n/a

AnalystConsensusTarget's Fair Value

n/a

-91.9%

47.1%

-91.9%

47.1%

You can edit this narrative until Sep 27 10:15 AM. Then, changes will post as Updates.

Author's Valuation

UK£0.0496.9% undervalued

AnalystConsensusTarget Fair Value

Narrative

Updates1

Shared on 26 Sep 25

Fair value Decreased 50%

The consensus analyst price target for Polarean Imaging has been halved, reflecting downward revisions driven by declining profitability and a lower future P/E, resulting in a new fair value estimate of £0.04. What's in the News Polarean Imaging submitted a new Phase III clinical trial protocol to the FDA to expand XENOVIEW's indication to include quantitative gas-exchange imaging.

AnalystConsensusTarget Fair Value

UK£0.04

96.9% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

69.31%

Medical Equipment revenue growth rate

8.27%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

8.46%

Calculation

US$2.11m

Earnings '28

46.63x

PE Ratio '28

US$98.30m

Market Cap '28

US$98.30m

Market Cap '28

1.47b

No. shares '28

US$0.07

Share Price '28

US$0.07 Share Price '28

Discounted to 2025 @ 7.62% p.a.

US$0.054

Fair Value '25

US$0.054 Fair Value '25

Converted to GBP @ 0.7498 USD/GBP Exchange Rate

UK£0.04

Fair Value '25